The RECHARGE revascularization trial in women and under-represented minority patients
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Consultant Fee/Honoraria/Speaker's Bureau - Heartflow; Abiomed; Elucid Bio; Valfix; Therox; Ablative Solutions; Miracor Medical SA; Ancora; Vectorious; Robocath; Neovasc; Apollo Therapeutics; Occlutech; Impulse Dynamics; Boehringer Ingelheim; Daiichi-Sankyo/Elil Lilly and Company; Abbott; Adona Medical; Millennia Biopharma; Oxitope; Cardiac Success; High Life; RCE; Aria; Elixir
- Equity/Stock(s)/Options - SpectraWave; Orchestra Biomed; Applied Therapeutics; Biostar Family of Funds; Aria; Cardiac Success; Valfix; Ancora; Cagent; Xenter
- Grant Support/Research Contract - V-Wave; Cardiovascular Systems Inc; Phillips; Biosense Webster; Abbott; Bioventrix; Vascular Dynamics; Shockwave; Abiomed; Pulnovo